ADVERTISEMENT
ADVERTISEMENT
Abstract illustration of a circuit board.
Overcoming Roadblocks in PROTAC Characterizations
Researchers require an accurate and high throughput method to evaluate proteolysis targeting chimera (PROTAC) interactions. 
Overcoming Roadblocks in PROTAC Characterizations
Overcoming Roadblocks in PROTAC Characterizations

Researchers require an accurate and high throughput method to evaluate proteolysis targeting chimera (PROTAC) interactions. 

Researchers require an accurate and high throughput method to evaluate proteolysis targeting chimera (PROTAC) interactions. 

Binding affinity

Abstract waves in red, orange, blue, and purple on a black background.
A Quick and Efficient Strategy for Affinity Screening
NanoTemper Technologies | Dec 7, 2023 | 1 min read
Researchers assessed the binding affinities of PROTAC binary and ternary complexes with Spectral Shift technology.
Conceptual illustration of molecular interactions.
A Solution for Measuring In-Solution Interactions 
NanoTemper Technologies | Dec 5, 2023 | 1 min read
Scientists used Spectral Shift assays to assess binding affinity and degradation of the oncogene regulator WDR5.
A Y-shaped pink, blue, and light green antibody is in focus on a background of blurred pink and purple color, with other antibodies out of focus in the background.
Phage Display: Finding the One in a Million
Shelby Bradford, PhD | Dec 4, 2023 | 10+ min read
A combinatorial approach enabled high-throughput screening of protein libraries for desired target binding.
An illustration of antibodies floating in solution.
Biotherapeutic Antibodies: Journey from the Benchtop to the Clinic
Cytiva | Aug 29, 2023 | 1 min read
Translational scientists employ surface plasmon resonance (SPR) to make informed decisions when choosing their lead antibody candidates. 
An illustration of caffeine molecules.
Visualizing Molecular Interactions without Labels
Cytiva | Aug 17, 2023 | 1 min read
Researchers use label-free surface plasmon resonance to measure affinity and binding kinetics in real time. 
Affinity versus Avidity: Differentiating Between Binding Phenomena  
Affinity versus Avidity: Differentiating Between Binding Phenomena  
The Scientist | Aug 10, 2023 | 1 min read
In this webinar, Tim Heiseler will discuss the importance of assay design when measuring binding kinetics and affinity values, as well as strategies to mitigate avidity effects.
small-molecule therapeutics treat cancer and other diseases
Scientists Take Aim at Disease-Causing RNAs Using Small-Molecule Drugs
Claire Asher | Apr 1, 2019 | 9 min read
Renewed interest from the biotech industry sparks hope for drugging the nucleic acid to treat cancer and other conditions.
Screening Goes In Silico
Carina Storrs | Feb 1, 2015 | 8 min read
Computational tools take some of the cost—and guesswork—out of drug discovery.
ADVERTISEMENT